Stay updated on Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.

Latest updates to the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added to the page; the funding-status notice about a lapse in government funding and the previous Revision: v3.4.1 were removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check20 days agoChange Detected- The page now displays a site-wide notice about government funding status and NIH Clinical Center operations, and the revision has been updated from v3.4.0 to v3.4.1.SummaryDifference0.2%

- Check28 days agoChange DetectedNew glossary display, a new 'Last Update Submitted that Met QC Criteria' label, 'No FEAR Act Data' label, and a site revision note 'Revision: v3.4.0', with capitalization changes such as 'Last Update Submitted that met QC Criteria' and 'No FEAR Act data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check42 days agoChange DetectedA minor revision update was applied: Revision: v3.3.4 replacing v3.3.3. This metadata change does not affect the study details, eligibility criteria, endpoints, or user-facing content on the page. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check63 days agoChange DetectedExpanded the study locations by adding numerous site locations across the US, Argentina, Australia, and Europe, broadening enrollment options. Removed the HHS Vulnerability Disclosure entry and several location groups.SummaryDifference4%

- Check91 days agoChange DetectedPublications section description updated to note that entries are automatically filled from PubMed and may not be about the study. Revision label updated from v3.2.0 to v3.3.2.SummaryDifference0.0%

Stay in the know with updates to Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib vs Everolimus in Metastatic Renal Cell Carcinoma Clinical Trial page.